These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20795948)

  • 21. Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.
    Ito G; Fujimoto T; Kamikawaji S; Kuwahara T; Iwatsubo T
    PLoS One; 2014; 9(5):e97988. PubMed ID: 24836358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
    Qing H; Wong W; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of the autophosphorylation sites of LRRK2.
    Kamikawaji S; Ito G; Iwatsubo T
    Biochemistry; 2009 Nov; 48(46):10963-75. PubMed ID: 19824698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways.
    Sancho RM; Law BM; Harvey K
    Hum Mol Genet; 2009 Oct; 18(20):3955-68. PubMed ID: 19625296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.
    Zhao J; Hermanson SB; Carlson CB; Riddle SM; Vogel KW; Bi K; Nichols RJ
    Biochem Soc Trans; 2012 Oct; 40(5):1158-62. PubMed ID: 22988882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.
    Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K
    PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson-Related LRRK2 Mutation R1628P Enables Cdk5 Phosphorylation of LRRK2 and Upregulates Its Kinase Activity.
    Shu Y; Ming J; Zhang P; Wang Q; Jiao F; Tian B
    PLoS One; 2016; 11(3):e0149739. PubMed ID: 26930193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
    Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
    Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LRRK2 dephosphorylation increases its ubiquitination.
    Zhao J; Molitor TP; Langston JW; Nichols RJ
    Biochem J; 2015 Jul; 469(1):107-20. PubMed ID: 25939886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
    Nguyen AP; Moore DJ
    Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LRRK2 transport is regulated by its novel interacting partner Rab32.
    Waschbüsch D; Michels H; Strassheim S; Ossendorf E; Kessler D; Gloeckner CJ; Barnekow A
    PLoS One; 2014; 9(10):e111632. PubMed ID: 25360523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
    Deng X; Dzamko N; Prescott A; Davies P; Liu Q; Yang Q; Lee JD; Patricelli MP; Nomanbhoy TK; Alessi DR; Gray NS
    Nat Chem Biol; 2011 Apr; 7(4):203-5. PubMed ID: 21378983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2.
    Gloeckner CJ; Boldt K; von Zweydorf F; Helm S; Wiesent L; Sarioglu H; Ueffing M
    J Proteome Res; 2010 Apr; 9(4):1738-45. PubMed ID: 20108944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
    Hamm M; Bailey R; Shaw G; Yen SH; Lewis J; Giasson BI
    J Neurosci Res; 2015 Oct; 93(10):1567-80. PubMed ID: 26123245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.
    Greggio E; Taymans JM; Zhen EY; Ryder J; Vancraenenbroeck R; Beilina A; Sun P; Deng J; Jaffe H; Baekelandt V; Merchant K; Cookson MR
    Biochem Biophys Res Commun; 2009 Nov; 389(3):449-54. PubMed ID: 19733152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.
    Ito G; Okai T; Fujino G; Takeda K; Ichijo H; Katada T; Iwatsubo T
    Biochemistry; 2007 Feb; 46(5):1380-8. PubMed ID: 17260967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
    Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
    Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions?
    Civiero L; Bubacco L
    Biochem Soc Trans; 2012 Oct; 40(5):1095-101. PubMed ID: 22988872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The R1441C mutation of LRRK2 disrupts GTP hydrolysis.
    Lewis PA; Greggio E; Beilina A; Jain S; Baker A; Cookson MR
    Biochem Biophys Res Commun; 2007 Jun; 357(3):668-71. PubMed ID: 17442267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
    Lu YW; Tan EK
    J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.